China Aims for 25% Global Drug Innovation by 2030

China has announced a five-year plan to boost its biomedical sector, aiming to develop 25% of global first-in-class drugs by 2030. The plan includes increasing research and development (R&D) and creating a pharmaceutical ecosystem focusing on innovative drugs. The Chinese pharmaceutical industry is projected to generate annual revenue of 3.5 trillion yuan (approximately $520 billion) by 2030, with ambitions for at least 50 companies to exceed $1.5 billion in annual revenue. Investors should note the focus on next-generation therapies and traditional Chinese medicine as growth drivers, indicating a significant shift toward innovation in China's drug market.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.